NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 923.8 DKK | +1.52% |
|
+4.61% | +32.26% |
| 10:45am | Wegovy weight loss sustained for four years in trial, Novo Nordisk says | RE |
| 09:16am | Novo Nordisk Taps Banks for Potential Bond Issue | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
909.9
DKK
Average target price
908.7
DKK
Spread / Average Target
-0.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.26% | 586B | |
| +29.98% | 682B | |
| -3.52% | 364B | |
| +18.59% | 327B | |
| +4.07% | 285B | |
| +16.46% | 240B | |
| +9.49% | 209B | |
| -8.96% | 203B | |
| +7.09% | 165B | |
| -1.22% | 161B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Sector Update: Health Care Stocks Lower Friday Afternoon